Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs.
Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia
Designation based on positive results from two Phase III trials
Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create a range of highly selective therapies for cancer.
Innovative Clinical Studies
Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies.
Our multiparametric phospho-proteomic platform enables the characterization of activated signaling networks within complex tissues and in discrete cell subsets.
Our Translational Medicine (TM) team are actively implementing MRD endpoints in our clinical trials to understand what treatments can drive to MRD undetectable levels.
Research in the Netherlands
At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. The Oss research centre is based in the heart of the Pivot Park Biotechnology Campus and has established relationships with both academic and commercial partners in Europe.